TRONTIER
Roche Doubles Down on Alzheimer’s with Next-Gen Amyloid-Lowering Drug Trontinemab
Roche; Alzheimer’s disease; trontinemab; amyloid-lowering drug; Brainshuttle; Phase III trial; TRONTIER studies; drug development; biomarkers; early intervention